Drug Profile

Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto

Latest Information Update: 27 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Advanced Proteome Therapeutics
Developer Advanced Proteome Therapeutics; Toronto Recombinant Antibody Centre
Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
05 Feb 2018 Advanced proteome therapeutics has patent protection for anticancer protein therapeutics in Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com